Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme

Drug Metabolism and Disposition

Volumn 40, Issue 9, 2012, Pages 1765-1770

  Amunugama, Hemali T ^a   Zhang, Haoming ^a   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; HEME; ISOENZYME; METHADONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INACTIVATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; SUICIDE SUBSTRATE;

ANALGESICS, OPIOID; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CARBON MONOXIDE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEME; HUMANS; KINETICS; METHADONE; NADP; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84865155030     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045971     Document Type: Article

References (45)

1. Anggård E, Gunne LM, Homstrand J, McMahon RE, Sandberg CG, and Sullivan HR (1975) Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 17:258-266.
2. Blobaum AL (2006) Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome p450 enzymes? Drug Metab Dispos 34:1-7.
3. Blobaum AL, Kent UM, Alworth WL, and Hollenberg PF (2002) Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein. Chem Res Toxicol 15:1561-1571. (Pubitemid 36008203)
4. Bunten H, Liang WJ, Pounder D, Seneviratne C, and Osselton MD (2011) CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 16:142-144.
5. Chang TK, Chen J, and Lee WB (2001) Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 299:874-882. (Pubitemid 33104954)
6. Chatterjee P and Franklin MR (2003) Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 31:1391-1397. (Pubitemid 37310329)
7. Clark JD (2008) Understanding methadone metabolism: a foundation for safer use. Anesthesiology 108:351-352.
8. Crowley JR and Hollenberg PF (1995) Mechanism-based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion. Drug Metab Dispos 23:786-793.
9. Davies HW, Britt SG, and Pohl LR (1986) Carbon tetrachloride and 2-isopropyl-4-pentenamide-induced inactivation of cytochrome P-450 leads to heme-derived protein adducts. Arch Biochem Biophys 244:387-392. (Pubitemid 16109534)
10. Foster DJ, Somogyi AA, and Bochner F (1999) Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 47:403-412. (Pubitemid 29161273)
11. Foti RS, Rock DA, Pearson JT, Wahlstrom JL, and Wienkers LC (2011) Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction. Drug Metab Dispos 39:1188-1195.
12. Gay SC, Zhang H, Wilderman PR, Roberts AG, Liu T, Li S, Lin HL, Zhang Q, Woods VL Jr, Stout CD, et al. (2011) Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity. Biochemistry 50:4903-4911.
13. Gerber JG, Rhodes RJ, and Gal J (2004) Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16:36-44. (Pubitemid 37532283)
14. Guzelian PS and Swisher RW (1979) Degradation of cytochrome P-450 haem by carbon tetrachloride and 2-allyl-2-isopropylacetamide in rat liver in vivo and in vitro. Involvement of non-carbon monoxide-forming mechanisms. Biochem J 184:481-489. (Pubitemid 10183582)
15. He K, Bornheim LM, Falick AM, Maltby D, Yin H, and Correia MA (1998) Identification of the heme-modified peptides from cumene hydroperoxide- inactivated cytochrome P450 3A4. Biochemistry 37:17448-17457. (Pubitemid 29013746)
16. He K, Falick AM, Chen B, Nilsson F, and Correia MA (1996a) Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital. Chem Res Toxicol 9:614-622. (Pubitemid 26123963)
17. He K, He YA, Szklarz GD, Halpert JR, and Correia MA (1996b) Secobarbital-mediated inactivation of cytochrome P450 2B1 and its active site mutants. Partitioning between heme and protein alkylation and epoxidation. J Biol Chem 271:25864-25872. (Pubitemid 26347417)
18. Hoag MK, Trevor AJ, Kalir A, and Castagnoli N Jr (1987) Phencyclidine iminium ion. NADPH-dependent metabolism, covalent binding to macromolecules, and inactivation of cytochrome(s) P-450. Drug Metab Dispos 15:485-490. (Pubitemid 17145321)
19. Hollenberg PF, Kent UM, and Bumpus NN (2008) Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 21:189-205. (Pubitemid 351219719)
20. Hutzler JM, Melton RJ, Rumsey JM, Schnute ME, Locuson CW, and Wienkers LC (2006) Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: evidence for complex heme interactions. Chem Res Toxicol 19:1650-1659. (Pubitemid 44975128)
21. Iribarne C, Berthou F, Baird S, Dréano Y, Picart D, Bail JP, Beaune P, and Ménez JF (1996) Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9:365-373. (Pubitemid 26079977)
22. Iribarne C, Dréano Y, Bardou LG, Ménez JF, and Berthou F (1997) Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 117:13-23. (Pubitemid 27063996)
23. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, and Hall SD (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290:1116-1125. (Pubitemid 29400251)
24. Jushchyshyn MI, Kent UM, and Hollenberg PF (2003) The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metab Dispos 31:46-52. (Pubitemid 36735257)
25. Jushchyshyn MI, Wahlstrom JL, Hollenberg PF, and Wienkers LC (2006) Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metab Dispos 34:1523-1529. (Pubitemid 44285394)
26. Kenaan C, Zhang H, and Hollenberg PF (2010) A quantitative high-throughput 96-well plate fluorescence assay for mechanism-based inactivators of cytochromes P450 exemplified using CYP2B6. Nat Protoc 5:1652-1658.
27. Kent UM, Bend JR, Chamberlin BA, Gage DA, and Hollenberg PF (1997) Mechanism-based inactivation of cytochrome P450 2B1 by N-benzyl-1- aminobenzotriazole. Chem Res Toxicol 10:600-608. (Pubitemid 27217218)
28. Kharasch ED, Hoffer C, Whittington D, Walker A, and Bedynek PS (2009) Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology 110:660-672.
29. Leppert W (2009) The role of methadone in cancer pain treatment - a review. Int J Clin Pract 63:1095-1109.
30. Li Y, Kantelip JP, Gerritsen-van Schieveen P, and Davani S (2008) Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 12:109-124. (Pubitemid 351570866)
31. Lin HL, Kent UM, and Hollenberg PF (2005) The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 313:154-164. (Pubitemid 40411339)
32. Lu WJ, Bies R, Kamden LK, Desta Z, and Flockhart DA (2010) Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug Metab Dispos 38:1308-1313.
33. Macdonald TL, Burka LT, Wright ST, and Guengerich FP (1982) Mechanisms of hydroxylation by cytochrome P-450: exchange of iron-oxygen intermediates with water. Biochem Biophys Res Commun 104:620-625.
34. Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, and Zhou SF (2009) Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 10:730-753.
35. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
36. Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch Biochem Biophys 395:57-68. (Pubitemid 33030143)
37. Sharma U, Roberts ES, and Hollenberg PF (1996) Formation of a metabolic intermediate complex of cytochrome P4502B1 by clorgyline. Drug Metab Dispos 24:1247-1253. (Pubitemid 26423066)
38. Sporkert F and Pragst F (2000) Determination of methadone and its metabolites EDDP and EMDP in human hair by headspace solid-phase microextraction and gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 746:255-264. (Pubitemid 30657943)
39. Sullivan HR and Due SL (1973) Urinary metabolites of dl-methadone in maintenance subjects. J Med Chem 16:909-913.
40. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, and Kharasch ED (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108:363-374. (Pubitemid 351304229)
41. Walsky RL, Astuccio AV, and Obach RS (2006) Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 46:1426-1438. (Pubitemid 44704203)
42. Wang H and Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598-610.
43. Ward DP, Trevor AJ, Kalir A, Adams JD, Baillie TA, and Castagnoli N Jr (1982) Metabolism of phencyclidine. The role of iminium ion formation in covalent binding to rabbit microsomal protein. Drug Metab Dispos 10:690-695. (Pubitemid 13223708)
44. Zhang H, Lin HL, Walker VJ, Hamdane D, and Hollenberg PF (2009) tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance. Mol Pharmacol 76:1011-1018.
45. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, and Hollenberg PF (2011) Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome P450-reductase complex. J Pharmacol Exp Ther 338:803-809.